Eris Lifesciences’ September-quarter net profit rose to ₹187.14 crore as domestic branded formulations revenue strengthened, led by diabetes products and new insulin and semaglutide launches.
Eris Lifesciences Ltd reported a sharp rise in quarterly profit on Monday, helped by stronger demand in its domestic branded formulations business, especially diabetes treatments. The company said consolidated net profit for the September quarter climbed 39.16% to ₹187.14 crore from ₹134.47 crore a year earlier, while revenue from operations increased to ₹892.37 crore from ₹792.41 crore.
The company’s chairman and managing director, Amit Bakshi, said in a statement that domestic branded formulations revenue grew 14% in the quarter, with its main therapy areas continuing to outpace the wider market. He said the diabetes franchise had gained momentum after the launch of insulin and semaglutide products, with growth of 18.5% compared with market growth of 16.1%.
Bakshi also said Eris’s in-house recombinant semaglutide has received approval for Phase 1 and Phase 3 clinical trials, a development that could broaden the company’s pipeline in the fast-growing metabolic disease segment. Third-party summaries of the results pointed to steady operating performance as well, with EBITDA of about ₹309 crore and a margin that was lower than a year earlier, suggesting the business is still balancing growth with rising costs.
Total expenses in the quarter rose to ₹702.86 crore from ₹622.83 crore a year earlier, the company’s filing showed. Eris shares ended the trading session 0.37% lower at ₹1,093.60 on the BSE, according to market data cited in the report.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
